康方生物(09926.HK)澄清目前各項業務發展一切正常
康方生物(09926.HK)公佈,已獲悉其股份昨日(5日)出現股價及成交量不尋常波動。經做出一切有關公司於合理情況下的查詢後,確認其並不知悉任何根據香港法例第571章證券及期貨條例第XIVA部須予披露的資料。
公司澄清,目前各項業務發展一切正常,對未來的發展和中國生物醫藥行業的發展充滿信心。
此外,公司提及目前開展的臨牀研究項目已超過80項。其商業化團隊體系搭建基本完成,並已經爲卡度尼利(PD-1/CTLA-4雙抗,研發代號:AK104)上市在全國做好充足的準備。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.